Summary: Blademy , the Côte d’Ivoire–based telemonitoring startup for metabolic diseases, today reports a series of operational and institutional milestones supported by FasterCapital ’s…
Abidjan, Côte d’Ivoire Central African Republic & Dubai, UAE
Blademy, the Côte d’Ivoire–based telemonitoring startup for metabolic diseases, today reports a series of operational and institutional milestones supported by FasterCapital’s ongoing work with EquityPilot. Progress includes a formal technology proposal submitted to the Minister of Employment and Social Protection, a signed institutional partnership with the national metabolic disease program (PNLMM/PMNT), and a finalized clinical protocol ready for ethics submission.
FasterCapital and EquityPilot continue to support Blademy’s current execution focus on clinical validation, public‑sector integration, and field-ready technology deployment, emphasizing milestone planning, fundraising readiness, and stakeholder introductions.
Blademy has moved from product development toward structured clinical and public‑sector engagement. Key advances include formalizing a ministerial proposal to integrate Blademy with the national single social protection number for continuous CMU validation; a signed partnership attestation with the PNLMM/PMNT and named clinical investigators; and a finalized randomized clinical protocol (200 pre‑identified T2D patients) ready for CNESVS submission.
What the Startup Delivers?
– Integrated platform connecting CE‑marked devices (Eaglenos EN410 glucose/uricemia reader and ZK‑B876 blood‑pressure monitor) with an offline-first mobile app tailored to older and low‑connectivity users.
– Clinically focused pilot protocol (12‑month timeline) embedded within the national UPEC network and Hôpital Militaire d’Abidjan’s endocrinology service.
– Data hosting and security compliant with national requirements, with AES‑256 encryption and strong authentication.
Current FasterCapital Support
FasterCapital is providing ongoing support through EquityPilot in the following areas:
– Milestone planning and execution follow‑up to meet regulatory and clinical timelines
– Fundraising readiness support and preparation of investor presentation materials
– Pitch and communication refinement for institutional and investor audiences
– Introductions to relevant ecosystem stakeholders to accelerate pilot deployment
– Strategic prioritization for near‑term operational scaling
Current Execution
Priorities Blademy’s current priorities are the CNESVS ethics submission and rapid recruitment of the pre‑identified 200 patients, field deployment of certified devices and the offline‑first mobile app, and operational integration with UPEC units to ensure clinician dashboards and alert workflows are operational.
Leadership Comment
Hesham Zreik, Founder and CEO of FasterCapital, said: ‘We’re pleased to continue supporting Blademy through EquityPilot. Our team is focused on current execution priorities, milestone tracking, and connecting the startup with relevant ecosystem stakeholders as it advances.’
About Blademy
Blademy is a Côte d’Ivoire–based digital health startup focused on telemonitoring for metabolic diseases. The company integrates certified connected devices, an offline-first app, clinician dashboards, and data sovereignty measures to support clinical management, population health monitoring, and public‑sector reimbursement integrity.
About FasterCapital
FasterCapital works with founders to turn plans into disciplined execution through milestone-based support, hands-on guidance, and improved fundraising readiness. With programs including EquityPilot, FasterCapital helps startups sharpen positioning, clarify priorities, and connect with relevant ecosystem stakeholders as they grow.
